Poland· PL-100505915
Loqtorzi
A toripalimab product containing toripalimabum, registered in Poland by TMC Pharma (EU) Ltd.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Toripalimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF13 (toripalimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Toripalimab · ATC L01FF13
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Toripalimabum
- Manufacturer
- TMC Pharma (EU) Ltd.
- Country
- Poland (PL)
- ATC code
- L01FF13
- ATC class
- Toripalimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04150199715806
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Toripalimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLoqtorzi 240 mgTopalliance Biosciences Europe
- CzechiaLOQTORZITopalliance Biosciences Europe Limited, Dublin
- FinlandLOQTORZITopalliance Biosciences Europe Limited
- IrelandLOQTORZI 240 mg concentrate for solution for infusionTopalliance Biosciences Europe Limited
- IcelandLOQTORZITopalliance Biosciences Europe Limited.
- NorwayLoqtorziTopalliance Biosciences Europe Limited
- SwedenLOQTORZI 240 mg Koncentrat till infusionsvätska, lösningTopalliance Biosciences Europe Limited
- United StatesLOQTORZICoherus Oncology, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Loqtorzi
- Liechtenstein · Loqtorzi
- Norway · Loqtorzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cae27903-f1a7-43a4-b498-d9a86f379ad9 GET /v1/drugs/cae27903-f1a7-43a4-b498-d9a86f379ad9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "240 mg",
"packaging": "Rpz ¦ EU/1/24/1853/001 ¦ 158205\n1 fiol. 6 ml\n¦ UR/Z/4c/113/26 - 04150199715806",
"substance": "Toripalimabum 240 mg",
"common_name": "Toripalimabum",
"pl_product_id": "100505915",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about toripalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.